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Abstract
As human papillomavirus (HPV) vaccines become available in less developed countries,
understanding women’s attitudes towards HPV vaccines can help guide approaches to
immunization programs. We assessed knowledge and interest in prophylactic HPV vaccines
among Kenyan women seeking women’s health services (N=147). They knew little about cervical
cancer or HPV vaccine. Most women (95%, 95% confidence interval [CI]: 92%, 99%), however,
were willing to have their daughters vaccinated with a vaccine that would prevent cervical cancer,
with preference for an inexpensive vaccine requiring fewer doses.
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1. Introduction
Of an estimated 493,000 new cases of cervical cancer diagnosed in the world each year,
80% occur in less developed countries [1]. East Africa has among the highest cervical
cancer incidence and mortality rates in the world [2]. Kenyan women face a cervical cancer
mortality rate that is approximately 14 times higher than that in the United States
(35/100,000 women vs. 2.4/100,000 women annually) [2,3]. This high mortality rate is most
likely attributable to a lack of cytology screening and early treatment programs, as well as
relatively high HIV prevalence [4,5]. In this setting, new prophylactic HPV vaccines offer
hope of preventing a large proportion of cervical cancer cases [6,7], because the potential
protection from HPV vaccine can offer benefits when other preventive screening options are
largely unavailable.
The World Health Organization (WHO) recommends that national immunization programs
include routine HPV immunization in areas where cervical cancer incidence is high and
introduction is programmatically feasible [8]. Vaccine demonstration projects may be
needed in areas of the less developed world with a high incidence of cervical cancer, HIV,
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malaria, sexually transmitted infections, or malnutrition. To guide these future HPV
immunization programs or demonstration projects in Africa, gathering data on acceptability
of HPV vaccines among African women is an essential step. Messages for healthcare
providers, public health educators, and community health workers can address these beliefs
in order to potentially increase HPV vaccine uptake. Research on HPV vaccine acceptability
among community members has focused on the industrialized world, with a small number of
studies in Latin America [9] and Asia [10–14]. In addition, two qualitative studies in
Uganda and South Africa offered preliminary assessments of national readiness for HPV
vaccine introduction [15,16]. We studied HPV vaccine acceptability among women in
Kisumu, Kenya, an African population with a high incidence of cervical cancer, but little or
no prior research on HPV vaccine acceptability.
2. Methods
The study was conducted at Ober Kamoth Health Center and Port Florence Community
Hospital, both located in a semi-urban region of Kisumu, Kenya. Ober Kamoth Health
Center is a public health facility, while Port Florence Community Hospital is a private health
facility. Female interviewers approached all women aged 15 to 49 years seeking maternal-
child health or family planning services during a one month period in 2007 and invited them
to participate in the study. All 147 women that interviewers approached (97 at Ober Kamoth
Health Center and 50 at Port Florence Community Hospital) agreed to participate. In mid
2007, HPV vaccine was not yet available in Kenya, but the vaccine had already been
licensed and recommended in the US [17]. Pap smear testing was available at both Ober
Kamoth Health Center and Port Florence Community Hospital, although no educational
campaigns to encourage cervical cancer screening existed in Kisumu or elsewhere in Kenya.
Interviewers administered questionnaires in English, Kiswahili, or Dhuluo, based on the
participant’s request. The questionnaire assessed willingness to get HPV vaccine for their
daughters if it became available in Kisumu (“How likely would you be to vaccinate your
daughter against HPV if it prevented cervical cancer? Assume the vaccine is free.”) Five
questions assessed willingness conditioned on whether the vaccine would prevent cervical
cancer alone, genital warts alone, or both conditions, or that the vaccine would require one
or three shots. Response options were “very likely”, “likely”, “neither likely nor unlikely”,
“unlikely”, or “very unlikely”. The questionnaire instructed women who did not have
daughters to answer the question as if they did. We coded responses into two categories,
“likely” and “unlikely” (with the response “neither likely nor unlikely” included in the
“unlikely” category). The questionnaire also assessed socio-demographic factors, awareness
of cancer, cervical cancer and cervical cancer screening, perceived access to cervical cancer
screening, HPV vaccine awareness, and factors affecting willingness to vaccinate against
HPV.
The primary outcome was willingness to vaccinate against HPV. We used McNemar’s test
to determine whether differences in responses to willingness questions were statistically
significant. We used the Fisher’s exact test to determine whether women recruited from the
two different health facilities differed.
3. Results
3.1 Characteristics of the sample
The 147 women surveyed had a median age of 25 years (range 15 to 45). Eighty-three
percent of women were married, and 90% reported a previous history of pregnancy. Thirty-
six percent were currently using a form of contraception. Thirty-one percent had received
schooling beyond the primary level. Seventy-five percent reported being Protestant. Only
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6% reported having formal employment. Two of the women had ever smoked. Women from
Ober Kamoth Health Center had a similar age, marital status, and contraception usage as
women from Port Florence Community Hospital, however, they were less likely to have
received schooling beyond the primary level (19% vs. 56%, p<0.001), and were less likely
to have formal employment (1% vs. 16%, p=0.001).
3.2. Awareness of cervical cancer and screening
Awareness of cervical cancer and cervical cancer screening was limited. While 89% of
women had heard of cancer, only 15% had heard of cervical cancer (Table). Nevertheless,
women in the study were concerned about cervical cancer; 71% of women reported that if
their daughters had cervical cancer it would be a “high threat”.
One woman had previously received cervical cancer screening. Among women who had
heard of cervical cancer, 10% knew that cervical cancer screening was available at their
health facilities.
3.3. Willingness to vaccinate against HPV
None of the women had heard of HPV vaccine before being in the study. Most women said
that they were likely to have their daughters immunized with HPV vaccine if it became
available in Kisumu and was free of charge. Ninety-five percent (95% CI: 92%, 99%)
responded that they were likely to have their daughters immunized if the vaccine protected
against cervical cancer, 94% (95% CI: 90%, 98%) were likely to have their daughters
immunized if the vaccine protected against genital warts, and 95% (95% CI: 92%, 99%)
were likely to have their daughters immunized if the vaccine protected against both cervical
cancer and genital warts. Thus, willingness did not differ when the vaccine was described as
preventing cervical cancer alone, or both cervical cancer and genital warts.
In response to willingness questions that varied the description of the dosing of HPV
vaccination, 86% (95% CI: 80%, 91%) of women said that they would be interested in
having their daughters receive HPV vaccine if only one shot was required. However, only
31% (95% CI: 23%, 38%) of women were interested in having their daughters receive HPV
vaccines if three shots were required. The lower acceptability of a three dose vaccine
regimen as compared to a one dose vaccine regimen was statistically significant (p<0.001).
Finally, among those who provided an amount, only 25% were willing to pay more than 100
Kenyan Shillings (2009 US$ 1.32) for the complete series.
Women from Ober Kamoth Health Center as compared to the women from Port Florence
Community Hospital were less likely to be interested in a vaccine which required three
doses (23% vs. 47%, p=0.003), and were less willing to pay more than 100 Kenyan Shillings
for the complete series (15% vs. 55%, p<0.001).
4. Discussion
East Africa has among the highest incidence of invasive cervical cancer in the world [2].
Highly effective prophylactic vaccines against HPV-16 and -18, the most common invasive
cervical cancer-associated HPV infection types, are available and currently in use in other
countries. In Kenya, HPV-16 and -18 were isolated in over 60% of women with invasive
cervical carcinoma, suggesting that HPV vaccines could have a large impact [7]. Many prior
efforts at cervical cancer prevention by cytological screening have been largely ineffective
in the region, due to limited cytology and treatment services, lack of knowledge about
cervical cancer screening, and implementation and cost barriers [18]. However, successful
universal immunization programs do exist, using various strategies such as expanded
Becker-Dreps et al. Page 3













programs for immunization (EPI) and national vaccine days. HPV immunization may thus
be a uniquely effective intervention for the prevention of most cervical cancer in Africa.
Awareness of cervical cancer, cervical cancer screening, and HPV vaccine was very low
among women in this African country, much lower than previously reported elsewhere in
less-developed countries [9,10]. Despite this low awareness level, most women in the study
were interested in having their daughters immunized against HPV infection. This
willingness to vaccinate is strikingly similar to women in both urban and rural regions of
China, where awareness of cervical cancer and HPV vaccine are relatively higher [10].
Women in our study were interested in vaccines that offered protection against cervical
cancer alone, as well as a vaccine that offered protection against both cervical cancer and
genital warts. We also found that women strongly preferred a vaccine that would require
only one dose as compared to a vaccine that would require three doses. These results
reported among women in Kisumu, Kenya were striking, and echo findings of low coverage
of the third dose of the HPV vaccine series in the United States [19].
Surveyed women were not willing to pay much for HPV vaccine; among those who
provided an amount, three-quarters were unwilling to pay more than US$1.32 for having
their daughters receive the HPV vaccine series. At the time of the study, the cost of either
the quadrivalent HPV vaccine (Gardasil®) or the bivalent HPV vaccine (Cervarix®)
approached US$400 [20,21]. While alternative financing of HPV vaccine for developing
world populations may allow the costs to be notably lower in several countries [22], even
these lower costs are likely to constitute a large proportion of Kenya’s annual per capita
health care expenditure, which was $95 in 2005 [23]. Kenyan women’s lack of willingness
to pay an amount that approaches the current cost for HPV vaccine highlights the
importance of international agencies to assist with the cost of HPV vaccine in less developed
countries, or the need for lower-cost vaccines.
The study’s strengths include the presentation of early data on an African population that
has a high incidence of invasive cervical cancer, but that has been the subject of little or no
prior research on HPV vaccine acceptability. The study’s limitations include the use of a
small sample from two health facilities, which may not be generalizable to the Kenyan
population as a whole. However, the women surveyed had similar educational attainment
[24], contraceptive use [25], and smoking prevalence [25] as women in nationally-
representative Kenyan data. Another limitation is that many of the women interviewed had
never heard of cervical cancer. Since so few women were aware of cervical cancer (22), we
were unable to determine whether willingness to pay and willingness to receive three doses
differed notably between women who were and who were not aware of cervical cancer. The
low awareness of cervical cancer found in this study brings to light potential educational
challenges for introduction of HPV vaccine in the region.
While larger studies of acceptability are required, this initial study among women from East
Africa shows that while women are interested in having their daughters receive HPV
vaccine, cost and multiple dosage requirements may present barriers to successful
implementation of an effective HPV immunization program in this region. The introduction
of HPV prophylactic vaccines will likely also require an education campaign that includes
basic information on cervical cancer and the role of screening and HPV vaccines in order to
achieve optimal prevention.
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Table
Understanding of Cervical Cancer and Willingness to Vaccinate against HPV in Kenyan Women (N=147)
CANCER AND CERVICAL CANCER N (%)
Have you ever heard of cancer? Yes 130 (89%)
Have you ever heard of cervical cancer? Yes 22 (15%)
If your daughter had cervical cancer, how serious a threat to her health would it be? High threat 101*(71%)
Moderate threat 37 (26%)
Low threat 4 (3%)
CERVICAL CANCER SCREENING AND AVAILABILITY OF HEALTH FACILITIES
Do you know of any method of screening for cervical cancer? Yes 0 (0%)†
Have you ever been screened for cervical cancer? Yes 1 (5%)†
How long did it take you to reach this health facility? Less than 1 hour 91* (65%)
1 to 3 hours 40 (28%)
Unsure 10 (7%)
Is cervical cancer screening available at this health facility? Yes 2 (10%)†
WILLINGNESS TO VACCINATE
Have you ever heard of the HPV vaccine before today? Yes 0 (0%)
 How likely would you be to vaccinate your daughter against HPV if…
…it prevented cervical cancer? (Assume the vaccine is free). Likely 139*(95%)
Unlikely 7 (5%)
…it prevented genital warts? (Assume the vaccine is free). Likely 136*(94%)
Unlikely 9 (6%)
….it prevented both cervical cancer and genital warts? (Assume the vaccine is free). Likely 139*(95%)
Unlikely 7 (5%)
…it requires three shots? Likely 45*(31%)
Unlikely 101 (69%)
…it requires only one shot? Likely 124*(86%)
Unlikely 21 (14%)
What is the most you would pay out of pocket to get your adolescent daughter vaccinated against
HPV?
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CANCER AND CERVICAL CANCER N (%)
Will pay what is asked 7 (6%)
Unsure 23
*
Numbers do not add up to 147 due to missing responses.
†
Among those who had previously heard of cervical cancer.
§
Percentages among those who provided an amount.
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